272 related articles for article (PubMed ID: 37188537)
21. Effect of APOE ε4 genotype on amyloid-β, glucose metabolism, and gray matter volume in cognitively normal individuals and amnestic mild cognitive impairment.
Li W; Li R; Yan S; Zhao Z; Shan Y; Qi Z; Lu J;
Eur J Neurol; 2023 Mar; 30(3):587-596. PubMed ID: 36448771
[TBL] [Abstract][Full Text] [Related]
22. Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment.
Knopman DS; Lundt ES; Therneau TM; Albertson SM; Gunter JL; Senjem ML; Schwarz CG; Mielke MM; Machulda MM; Boeve BF; Jones DT; Graff-Radford J; Vemuri P; Kantarci K; Lowe VJ; Petersen RC; Jack CR;
JAMA Neurol; 2021 Feb; 78(2):217-228. PubMed ID: 33074304
[TBL] [Abstract][Full Text] [Related]
23. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
[TBL] [Abstract][Full Text] [Related]
24. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.
Desikan RS; McEvoy LK; Holland D; Thompson WK; Brewer JB; Aisen PS; Andreassen OA; Hyman BT; Sperling RA; Dale AM;
AJNR Am J Neuroradiol; 2013 Mar; 34(3):505-10. PubMed ID: 22976236
[TBL] [Abstract][Full Text] [Related]
25. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
26. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
[TBL] [Abstract][Full Text] [Related]
27. Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex,
Therriault J; Pascoal TA; Benedet AL; Tissot C; Savard M; Chamoun M; Lussier F; Kang MS; Berzgin G; Wang T; Fernandes-Arias J; Massarweh G; Soucy JP; Vitali P; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
Neurology; 2021 Feb; 96(7):e975-e985. PubMed ID: 33443136
[TBL] [Abstract][Full Text] [Related]
28. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease.
Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT
JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823
[TBL] [Abstract][Full Text] [Related]
29. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
Ozlen H; Pichet Binette A; Köbe T; Meyer PF; Gonneaud J; St-Onge F; Provost K; Soucy JP; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
JAMA Neurol; 2022 Oct; 79(10):1025-1035. PubMed ID: 35994280
[TBL] [Abstract][Full Text] [Related]
30. APOE ε4 is associated with decreased synaptic density in cognitively impaired participants.
He K; Li B; Wang J; Wang Y; You Z; Chen X; Chen H; Li J; Huang Q; Guo Q; Huang YH; Guan Y; Chen K; Zhao J; Deng Y; Xie F
Alzheimers Dement; 2024 May; 20(5):3157-3166. PubMed ID: 38477490
[TBL] [Abstract][Full Text] [Related]
31. Sex modulates the ApoE ε4 effect on brain tau deposition measured by
Liu M; Paranjpe MD; Zhou X; Duy PQ; Goyal MS; Benzinger TLS; Lu J; Wang R; Zhou Y
Theranostics; 2019; 9(17):4959-4970. PubMed ID: 31410194
[TBL] [Abstract][Full Text] [Related]
32. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
33. Association of
La Joie R; Visani AV; Lesman-Segev OH; Baker SL; Edwards L; Iaccarino L; Soleimani-Meigooni DN; Mellinger T; Janabi M; Miller ZA; Perry DC; Pham J; Strom A; Gorno-Tempini ML; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Neurology; 2021 Feb; 96(5):e650-e661. PubMed ID: 33262228
[TBL] [Abstract][Full Text] [Related]
34. Profiles of β-Amyloid Peptides and Key Secretases in Brain Autopsy Samples Differ with Sex and APOE ε4 Status: Impact for Risk and Progression of Alzheimer Disease.
Nyarko JNK; Quartey MO; Pennington PR; Heistad RM; Dea D; Poirier J; Baker GB; Mousseau DD
Neuroscience; 2018 Mar; 373():20-36. PubMed ID: 29331531
[TBL] [Abstract][Full Text] [Related]
35. APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression.
Dincer A; Chen CD; McKay NS; Koenig LN; McCullough A; Flores S; Keefe SJ; Schultz SA; Feldman RL; Joseph-Mathurin N; Hornbeck RC; Cruchaga C; Schindler SE; Holtzman DM; Morris JC; Fagan AM; Benzinger TLS; Gordon BA
Sci Transl Med; 2022 Nov; 14(671):eabl7646. PubMed ID: 36383681
[TBL] [Abstract][Full Text] [Related]
36. Imaging Biomarkers of Alzheimer Disease in Multiple Sclerosis.
Zeydan B; Lowe VJ; Reichard RR; Przybelski SA; Lesnick TG; Schwarz CG; Senjem ML; Gunter JL; Parisi JE; Machulda MM; Vemuri P; Mielke MM; Knopman DS; Petersen RC; Jack CR; Kantarci OH; Kantarci K
Ann Neurol; 2020 Apr; 87(4):556-567. PubMed ID: 31970802
[TBL] [Abstract][Full Text] [Related]
37. Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later.
Nägga K; Gustavsson AM; Stomrud E; Lindqvist D; van Westen D; Blennow K; Zetterberg H; Melander O; Hansson O
Neurology; 2018 Jan; 90(1):e73-e81. PubMed ID: 29196581
[TBL] [Abstract][Full Text] [Related]
38.
Nedelska Z; Przybelski SA; Lesnick TG; Schwarz CG; Lowe VJ; Machulda MM; Kremers WK; Mielke MM; Roberts RO; Boeve BF; Knopman DS; Petersen RC; Jack CR; Kantarci K
Neurology; 2017 Sep; 89(13):1391-1399. PubMed ID: 28842444
[TBL] [Abstract][Full Text] [Related]
39. Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults.
McSweeney M; Pichet Binette A; Meyer PF; Gonneaud J; Bedetti C; Ozlen H; Labonté A; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
Neurology; 2020 Mar; 94(11):e1190-e1200. PubMed ID: 32015176
[TBL] [Abstract][Full Text] [Related]
40. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.
McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S
J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
